Tekmira tumbles on firm's hesitancy to use Ebola drug
This article was originally published in Scrip
Executive Summary
Shares of Tekmira Pharmaceuticals tumbled 13.4% on 14 August after the company's CEO expressed some doubt about using the firm's experimental Ebola drug anytime soon during the current outbreak in West Africa – instead wanting to stay focused on its Phase I trial of TKM-Ebola, an RNA interference therapeutic.